免疫学:タンパク質による外科手術

Same author

Zapnometinib treatment and influenza A virus infection modulate the HLA class I ligandome in human lung adenocarcinoma cells.

Frontiers in immunology·2026

Same author

Correction: Promiscuous class II-binding SARS-CoV-2-nuc derived vaccine-peptide induced extensive conventional, innate and unconventional T cell responses.

Frontiers in immunology·2026

Same author

Personalised multipeptide-based T-cell activator for chronic lymphocytic leukaemia: an open-label, single-centre, phase 1 study.

The Lancet. Haematology·2026

Same author

EBV infection and HLA-DR15 jointly drive multiple sclerosis by myelin peptide presentation.

Cell·2026

Same author

Promiscuous class II-binding SARS-CoV-2-nuc derived vaccine-peptide induced extensive conventional, innate and unconventional T cell responses.

Frontiers in immunology·2025

Same author

Case Report: A neoantigen-targeting peptide vaccine combined with checkpoint inhibition induces tumor regression and long-term remission in a pediatric patient with metastatic hepatocellular carcinoma.

Frontiers in immunology·2025

Same journal

Six ways to put the public at the heart of science and policy.

Nature·2026

Same journal

The complex truth about trust in science.

Nature·2026

Same journal

Have people stopped trusting science? The data tell a surprising story.

Nature·2026

Same journal

How FAIR data are helping to build trust in science.

Nature·2026

Same journal

Scientists should recognize their own political biases to build public trust.

Nature·2026

Same journal

Harmonizing standards and resources for the medical genome.

Nature·2026

関連する実験動画

免疫学:タンパク質による外科手術

関連する概念動画

Zapnometinib treatment and influenza A virus infection modulate the HLA class I ligandome in human lung adenocarcinoma cells.

Correction: Promiscuous class II-binding SARS-CoV-2-nuc derived vaccine-peptide induced extensive conventional, innate and unconventional T cell responses.

Personalised multipeptide-based T-cell activator for chronic lymphocytic leukaemia: an open-label, single-centre, phase 1 study.

EBV infection and HLA-DR15 jointly drive multiple sclerosis by myelin peptide presentation.

Promiscuous class II-binding SARS-CoV-2-nuc derived vaccine-peptide induced extensive conventional, innate and unconventional T cell responses.

Case Report: A neoantigen-targeting peptide vaccine combined with checkpoint inhibition induces tumor regression and long-term remission in a pediatric patient with metastatic hepatocellular carcinoma.

Six ways to put the public at the heart of science and policy.

The complex truth about trust in science.

Have people stopped trusting science? The data tell a surprising story.

How FAIR data are helping to build trust in science.

Scientists should recognize their own political biases to build public trust.

Harmonizing standards and resources for the medical genome.

関連する実験動画

免疫学:タンパク質による外科手術

関連する概念動画

関連記事

Zapnometinib treatment and influenza A virus infection modulate the HLA class I ligandome in human lung adenocarcinoma cells.

Correction: Promiscuous class II-binding SARS-CoV-2-nuc derived vaccine-peptide induced extensive conventional, innate and unconventional T cell responses.

Personalised multipeptide-based T-cell activator for chronic lymphocytic leukaemia: an open-label, single-centre, phase 1 study.

EBV infection and HLA-DR15 jointly drive multiple sclerosis by myelin peptide presentation.

Promiscuous class II-binding SARS-CoV-2-nuc derived vaccine-peptide induced extensive conventional, innate and unconventional T cell responses.

Case Report: A neoantigen-targeting peptide vaccine combined with checkpoint inhibition induces tumor regression and long-term remission in a pediatric patient with metastatic hepatocellular carcinoma.

Six ways to put the public at the heart of science and policy.

The complex truth about trust in science.

Have people stopped trusting science? The data tell a surprising story.

How FAIR data are helping to build trust in science.

Scientists should recognize their own political biases to build public trust.

Harmonizing standards and resources for the medical genome.